Yves Lachance

Dr. Lachance was named Vice-President Quality & Compliance in September 2021, bringing strength in regulatory, quality, and compliance to the management team. Previously, Dr. Lachance was Co-founder and VP Product Development and Regulatory Affairs at diaMentis, a private company developing a simple and reliable solution in personalised medicine for clinical use. He has also served as a consultant and advisor with various pharmaceutical, cosmetic, natural healthcare products and medical devices companies, collaborating on a range of projects from product development to commercialization and including compliance and regulatory strategies. Prior to that, Dr. Lachance held increasingly more responsible positions in quality control, CMC and process development, regulatory affairs and quality assurance at Aeterna Zentaris. Dr. Lachance holds a B.Sc. in biochemistry and a Ph.D. in molecular endocrinology from Laval University and did a postdoctoral fellowship at Sherbrooke University in collaboration with the Canadian Department of Agriculture. His research focused on the isolation, cloning and characterization of complementary DNAs (cDNA) and genes of the main enzymes involved in the biosynthesis of all class of hormonal steroids, namely the Human 3 beta- hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase type I and Type II, Human 17β-Hydroxysteroid Dehydrogenase Type I and Type II and Human type II 5 α-reductase.